Matinas BioPharma Files Definitive Proxy Statement
Ticker: MTNB · Form: DEF 14A · Filed: Mar 3, 2025 · CIK: 1582554
| Field | Detail |
|---|---|
| Company | Matinas Biopharma Holdings, Inc. (MTNB) |
| Form Type | DEF 14A |
| Filed Date | Mar 3, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, sec-filing, governance
TL;DR
Matinas BioPharma dropped its proxy statement. Get ready for shareholder votes.
AI Summary
Matinas BioPharma Holdings, Inc. filed its definitive proxy statement on March 3, 2025, for the fiscal year ending December 31, 2024. The filing, under SEC Act of 1934, concerns the company's annual meeting and related shareholder matters. The company is located at 1545 Route 206 South, Suite 302, Bedminster, NJ 07921.
Why It Matters
This filing provides shareholders with crucial information regarding upcoming votes and company governance, impacting their investment decisions.
Risk Assessment
Risk Level: low — This is a routine regulatory filing (DEF 14A) and does not contain new financial or operational information that would inherently increase risk.
Key Numbers
- 20250303 — Filing Date (The date the definitive proxy statement was filed with the SEC.)
- 1231 — Fiscal Year End (Indicates the end of the company's fiscal reporting period.)
Key Players & Entities
- Matinas BioPharma Holdings, Inc. (company) — Registrant
- 0001582554 (company) — Central Index Key
- 1545 ROUTE 206 SOUTH (company) — Business Address
- BEDMINSTER, NJ 07921 (company) — Business Address
FAQ
What is the purpose of a DEF 14A filing?
A DEF 14A filing, or definitive proxy statement, is used by companies to solicit proxies from shareholders for an upcoming shareholder meeting, providing details on matters to be voted upon.
When was this specific proxy statement filed?
This definitive proxy statement was filed on March 3, 2025.
What is the company's Central Index Key (CIK)?
The Central Index Key for Matinas BioPharma Holdings, Inc. is 0001582554.
Where is Matinas BioPharma Holdings, Inc. located?
The company's business and mailing address is 1545 Route 206 South, Suite 302, Bedminster, NJ 07921.
Under which SEC Act is this filing made?
This filing is made pursuant to Section 14(a) of the Securities Exchange Act of 1934.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on March 3, 2025 regarding Matinas BioPharma Holdings, Inc. (MTNB).